Insulin analog shows blood glucose potential in trial

10/31/2012 | Modern Medicine

Data from a midstage trial revealed the basal insulin analog LY2605541 showed blood glucose benefits comparable to those of insulin glargine but fared better in reducing patients' weight and variability in glucose readings. Researchers also found the new agent helped lessen the frequency of nocturnal hypoglycemia by 48% compared with glargine. The findings appear in Diabetes Care.

View Full Article in:

Modern Medicine

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX